Biostatistics and Epidemiology

Grants and Contracts

Biostatistics and Epidemiology Division Grants


The Division of Biostatistics and Epidemiology provides support with grant writing to investigators from WCMC and outside research groups with overlapping research interests. It is highly recommended that the biostatistician be included in the proposal with percent FTE support.

Prior to grant submission, the following information needs to be provided to the biostatistician involved:

  • If this is a sub-award from another institution, we suggest you send the following at least 3 weeks before the deadline:
    • Funding agency
    • Submission date
    • Title of proposal
    • Proposed start and end date
    • Principal Investigator(s)
    • Our faculty’s role
    • % FTE over the proposed years
    • Annual direct costs
    • An updated version of the full application
  • If this is a grant submission from another department at WCMC, we suggest you send the above information at least 2 weeks before the deadline. The related Electronic Routing Form (ERF) would be routed through the Department of Public Health as a collaborating department.


SELECTED LIST OF CURRENT GRANTS:

Targeting the Obesity-Inflammation-COX-Aromatase Axis to Lower Breast Cancer Risk
Kathy Zhou, PhD (In collaboration with the Department of Medicine, P.I.: Andrew Dannenberg, M.D.)
09/16/2011 – 07/31/2016
National Institutes of Health/National Cancer Institute
The major goal of this project is to develop novel strategies to reduce obesity-related inflammation and aromatase expression in the mammary gland leading to a decreased risk of hormone receptor-positive breast cancer.  

MALT1 Targeted Therapy for B-Cell Lymphoma
Zhengming Chen, PhD (In collaboration with the Department of Medicine, P.I.: Ari Melnick, M.D.)
08/01/2014 – 07/31/2019
National Cancer Institute, NIH
This grant will study the targeted therapies of a new inhibitor of MALT1, a protease and scaffolding protein involved in the B-cell receptor (BCR) signaling pathway. This inhibitor has been shown to effectively kill a most chemoresistant subtype of Diffuse Large B-cell Lymphoma (DLBCL): ABC-DLBCL. This study will first determine the genetic background of responders to MALT1 inhibition, then discover the possible resistance mechanisms, and finally design and test combination therapies that combine MALT1 inhibitor and existing drugs. The proposed approaches include unbiased high throughput screening such as next generation sequencing. It requires cutting-edge bioinformatical and biostatistical methodology to analyze and interpret the resulting data.

Targeting EZH2 in Germinal Center Derived B-Cell Lymphoma
Zhengming Chen, PhD (In collaboration with the Department of Medicine, P.I.: Ari Melnick, M.D.)
08/06/2014 – 07/31/2019
National Cancer Institute, NIH
The grant will investigate the effective therapies of B-cell lymphomas by targeting a H3K27 histone methyltransferase called EZH2. It will first explore the genetic and epigenetic determinants linked to EZH2 dependency in B-cell lymphomas, and then identify the mechanisms through which acquired resistance might develop to EZH2 inhibition. State of the art correlative studies will then be carried out to validate the pharmacodynamics and tumor background of lymphomas susceptible of EZH2 inhibitors in patients.

EIF4E-targeted Therapy in Lymphomas
Zhengming Chen, PhD
(In collaboration with the Department of Hematology and Medical Oncology, P.I.: Leandro Cerchietti, M.D.)
10/1/2013 – 9/30/2016
Leukemia and Lymphoma Society (LLS) Translational Research grant
This grant aims to determine the effect of an oncogene called eIF4E in Diffuse Large B-cell Lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma among adults, in the hope of finding a better chemotherapy for treating DLBCL patients. As part of the proposal, Dr. Chen will co-supervise a graduate student and provide statistical support for animal and patient studies and with RNAseq and RIPseq analysis.


CURRENT CONTRACTS:

Department of Psychiatry
Samprit Banerjee, PhD,
PI
7/1/2014 – 6/30/2015

Department of Anesthesiology
Linda Gerber, PhD,
PI
9/1/2014 – 8/31/2015

Division of Hematology and Medical Oncology
Linda Gerber, PhD, PI
7/1/2014 – 6/30/2015

Division of Hematology and Medical Oncology (Lymphoma)
Zhengming Chen, PhD, PI
7/1/2014 – 6/30/2015

Department of Radiology
Linda Gerber, PhD, PI
7/1/2014 – 6/30/2015

Burke Medical Center
Linda Gerber, PhD,
PI
4/1/2014 – 3/31/2015

Department of Pediatrics
Linda Gerber, PhD, PI
9/1/2014 – 8/31/2015

Departments of Neurology and Neurological Surgery
Linda Gerber, PhD, PI
1/1/2015 – 6/30/2015

Center for Advanced Digestive Care
Xi Kathy Zhou, PhD,
PI
7/1/2014 – 6/30/2015


SELECTED PAST GRANTS:

Molecular Targeting of diffuse large B-Cell Lymphoma
Paul Christos DrPH (In collaboration with the Department of Medicine, P.I.: Ari Melnick, M.D.)
1/20/2010 – 12/31/2014
National Institutes of Health
1) Developing chemical-mimetics of RI-BPI, 2) determining the mechanism and efficacy of cell killing of RI-BPI and derivatives alone and in combination in a spectrum of DLBCL cell lines in vitro and in vivo, 3) determining the response of primary DLBCLs to BPI ex vivo and identify biomarkers predictive of response to RI-BPI, and finally 4) to translate BCL6 targeted therapy to the clinic and determine the safety, activity, and optimal dosing of RI-BPI in patients with BCL-6-positive DLBCL.  By the end of the funding period, we expect to be moving peptidomimetic BCL6 inhibitor drugs into phase II clinical trials.   

Microtube dependent AR signaling predicts taxane sensitivity
Kathy Zhou, PhD
(In collaboration with the Department of Medicine, P.I.: Paraskevi Giannakakou, M.D.)
07/01/2009 – 06/30/2014
National Institutes of Health (NIH)
The purpose of this project is to identify how modulation of the lethal-phenotype-survival transcription factor AR following Taxol treatment determines clinical response and to assess the role of tubulin acetylation as a predictive biomarker for taxane activity in castrate-resistant metastatic prostate cancer patients.

Center of Excellence in Health Disparities Research
Linda Gerber, PhD
(In collaboration with the Department of Medicine, P.I.: Carla Boutin-Foster, M.D.)
7/25/2009 – 5/31/2014
National Center on Minority Health and Health Disparities (NCMHD)
The purpose of this project is to create an interdisciplinary academic and community research enterprise that will expand the capacity for conducting cutting-edge and trans-disciplinary research that will contribute to improving minority health and reducing health disparities in cardiovascular disease and cancer in Central Harlem and the South Bronx.

Comprehensive Prostate Cancer Characterization by Genomic and Transcriptomic Profiling
Madhu Mazumdar, PhD (In collaboration with the Department of Pathology, P.I.: Mark Rubin, M.D.)
National Cancer Institute
08/01/2011 – 07/31/2013
The overall goal of this proposal is to discover and validate prostate cancer (PCA) specific biomarkers that can be non-invasively detected in the urine. We have taken a Systems Biology approach integrating state-of-the-art RNA-sequencing (RNA-seq) and DNA 6.0 single nucleotide polymorphism (SNP) arrays with novel computational approaches for analysis.

Communication between Home Health Nurses and Physicians: The Impact on Hospital Readmission
Linda Gerber, PhD
(In collaboration with the Department of Public Health P.I.: Matthew Press, M.D.)
01/15/2012 – 06/14/2013
Aetna Foundation
The objective of this project is to assess the quality of communication between home health nurses and physicians and determine its association with risk of readmission.

Thromboregulation in Occlusive Vascular Diseases
Paul Christos, DrPH
(In collaboration with the Department of Medicine, P.I.: Aaron J. Marcus, M.D.)
5/01/2009 – 4/30/2013
National Institutes of Health (NIH)
Researchers of this project will study the molecular biology and function of CD39 in occlusive cerebrovascular diseases with emphasis on: A) Regulation of CD39 activity via tissue- and disease-specific expression of alternatively spliced variants in patients with atherothrombotic and cryptogenic stroke vs. normal controls; B) Differences in activities and ADPase/ATPase activity ratio of endogenous CD39 in blood cells of patients with stroke. Our long-range goal is an apyrase-based treatment of patients with platelet-driven occlusive vascular disorders which our accumulated data suggest would be safe and effective.


CONTACT US

  • Division Office
  • (646) 962-8020
More

Selected Recent Publications

Top of page